An understanding of cell type-specific CCL2 production may ultimately enable the targeting of this chemokine for enhancing or inhibiting immune cell recruitment to the brain during specific stages of neuroinflammatory and neurodegenerative diseases. The gene discussed is CCL2; the disease is neurodegenerative disease.